Načítá se...
Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis
There is a significant unmet need for safe and effective anti‐inflammatory treatment for cystic fibrosis. The aim of this study was to evaluate the safety of acebilustat, a leukotriene A4 hydrolase inhibitor, and its effect on inflammation biomarkers in patients with cystic fibrosis. Seventeen patie...
Uloženo v:
| Vydáno v: | Clin Transl Sci |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5351012/ https://ncbi.nlm.nih.gov/pubmed/27806191 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12428 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|